Dr. Carolyn Y. Muller
Claim this profileUniversity of New Mexico Cancer Center
Studies Endometrial Cancer
Studies Parotid Gland Cancer
23 reported clinical trials
44 drugs studied
Area of expertise
1Endometrial Cancer
Stage IV
HER2 positive
Stage I
2Parotid Gland Cancer
Stage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Carolyn Y. Muller is currently running
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
Behavioral Weight Loss + Progestin
for Endometrial Hyperplasia
Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of AEH in this age group. Hysterectomy with removal of the fallopian tubes and ovaries is 100% effective in preventing endometrial cancer, but this approach results in infertility. Fertility-sparing treatments exist, such as treatment with oral or intrauterine progestin, but these treatments do not work uniformly and do not combat the underlying cause of endometrial cancer, which is obesity and metabolic syndrome. Additionally, up to 41% of women on progestin eventually experience relapse of AEH or endometrial cancer. Third, many patients have insulin resistance that may worsen with progestin therapy. Thus, to improve treatment of AEH and grade 1 endometrial cancer, prevent and reverse endometrial cancer, and allow women to preserve their fertility, the investigators must integrate an effective weight loss strategy to be given with progestin treatment. It is the hypothesis that premenopausal women with AEH desire uterine preservation will be more likely to have atypia-free uterine preservation at one year if they receive progestin in combination with a behavioral weight loss intervention versus progestin plus enhanced usual care.
Recruiting1 award Phase 2
More about Carolyn Y. Muller
Clinical Trial Related1 year of experience running clinical trials · Led 23 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Carolyn Y. Muller has experience with
- Paclitaxel
- Pembrolizumab
- External Beam Radiation Therapy
- Cisplatin
- Quality-of-Life Assessment
- Questionnaire Administration
Breakdown of trials Carolyn Y. Muller has run
Endometrial Cancer
Parotid Gland Cancer
Ovarian Cancer
Cervical Adenocarcinoma
Relapse
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Carolyn Y. Muller specialize in?
Is Carolyn Y. Muller currently recruiting for clinical trials?
Are there any treatments that Carolyn Y. Muller has studied deeply?
What is the best way to schedule an appointment with Carolyn Y. Muller?
What is the office address of Carolyn Y. Muller?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.